Skip to main content
. Author manuscript; available in PMC: 2009 Jul 21.
Published in final edited form as: Pharmacogenet Genomics. 2007 Sep;17(9):719–729. doi: 10.1097/FPC.0b013e32810f2e3c

Fig. 2.

Fig. 2

Odds ratios for Lys65 variant on probability of requiring multiple drugs to achieve BP control. Odds ratios < 1 indicate lower likelihood of Lys65 variant carriers requiring as many drugs as Glu65Glu individuals to achieve BP control. Odds ratios > 1 indicate higher likelihood of requiring more drugs than Glu65Glu individuals. Model 1 is adjusted for age, race, and sex. Model 2 is adjusted for all model 1 variables plus baseline SBP and DBP, BMI, and history of heart failure, diabetes, renal insufficiency, and left ventricular hypertrophy. Panel A is verapamil SR monotherapy patients and Panel B is stable background therapy patients. BP, blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure.